Nuclea Biotechnologies Partners with IBL-America
News Feb 25, 2014
Nuclea Biotechnologies, Inc. has recently announced that Immuno-Biological Laboratories Inc., (IBL-America) would be their primary US distributor for the serum HER-2/neu kits.
IBL-America, based in Minneapolis, MN, is a distributor of high quality diagnostic assays in various areas including autoimmunity, endocrinology, infectious disease, oncology, and neuroscience and offers technical laboratory services as well.
Nuclea is a specialist in serum based oncoprotein diagnostics and offers tests for In Vitro Diagnostic (IVD) and Research Use Only (RUO). Nuclea provides the only FDA-cleared through 510(k) IVD ELISA test for the measurement of serum HER-2/neu in the management and monitoring of women with metastatic breast cancer.
This microtiter based test enables laboratories to measure the level of HER-2/neu in serum in a cost-efficient and validated manner. This test is reimbursed by insurance companies and has a unique CPT code 83950.
Additionally, the two companies will coordinate joint marketing efforts for the serum HER-2/neu kits.
“As we continue to see the market respond to our serum HER-2/neu test, we’ve been securing partners who have strong distribution channels,” said Patrick Muraca, President and CEO of Nuclea. “IBL-America has a proven track record and I’m excited to have them as a partner.”
Mark Kowal, President and CEO of IBL-America stated “We, at IBL-America, are excited about the opportunity to work with the professionals at Nuclea. The HER-2/neu test is an excellent addition to our line of oncology products and we welcome this promising joint venture.”
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019